- Home
- PROP vs COEP Comparison
PROP vs COEP Comparison
Compare PROP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROP | COEP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6M | 100.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PROP | COEP |
|---|---|---|
| Price | $2.02 | $14.60 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 86.1K |
| Earning Date | 02-15-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $166,577,000.00 | $500,996.00 |
| Revenue This Year | $3,967.26 | N/A |
| Revenue Next Year | $71.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $6.22 |
| 52 Week High | $10.58 | $21.41 |
Technical Indicators
Market Signals| Indicator | PROP | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 64.41 | 42.43 |
| Support Level | $1.71 | $13.74 |
| Resistance Level | $1.94 | $16.05 |
| Average True Range (ATR) | 0.11 | 0.78 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 94.68 | 17.79 |
Price Performance
Historical ComparisonAbout PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.